Design of an in-dwelling cannula for convection-enhanced delivery

Journal of Neuroscience Methods

Volumn 196, Issue 1, 2011, Pages 118-123

  Rosenbluth, Kathryn H ^a   Luz, Matthias ^b   Mohr, Erich ^b   Mittermeyer, Stephan ^c   Bringas, John ^a   Bankiewicz, Krystof S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MedGenesis Therapeutix Inc   (Canada)

^c BrainLAB   (Germany)

Author keywords

Cannula; Convection enhanced delivery; Infusion; MRI; Neuro oncology; Neurodegeneration; Non human primate

Indexed keywords

GADOTERIDOL;

ANIMAL EXPERIMENT; ARTICLE; CANNULA; CONTRAST ENHANCEMENT; CONVECTION ENHANCED DELIVERY; DEGENERATIVE DISEASE; DRUG DELIVERY SYSTEM; INFUSION; NEUROIMAGING; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; ONCOLOGY; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY;

ANIMALS; BRAIN; CATHETERIZATION; CONTRAST MEDIA; CONVECTION; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; FOLLOW-UP STUDIES; HETEROCYCLIC COMPOUNDS; MACACA MULATTA; MAGNETIC RESONANCE IMAGING; ORGANOMETALLIC COMPOUNDS; REPRODUCIBILITY OF RESULTS;

EID: 79951557738     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2010.12.022     Document Type: Article

References (20)

1. Bankiewicz K.S., Eberling J.L., Kohutnicka M., Jagust W., Pivirotto P., Bringas J., et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000, 164(1):2-14.
2. Bobo R.H., Laske D.W., Akbasak A., Morrison P.F., Dedrick R.L., Oldfield E.H., et al. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci USA 1994, 91:2076-2080.
3. Chen M.Y., Lonser R.R., Morrison P.F., Governale L.S., Oldfield E.H. Variables affecting convection-enhanced delivery to the striatum: a systematic examination of rate of infusion, cannula size, infusate concentration, and tissue-cannula sealing time. J Neurosurg 1999, 90(2):315-320.
4. Fiandaca M., Varenika V., Eberling J., McKnight T., Bringas J., Pivirotto P., et al. Real-time MR imaging of adeno-associated viral vector delivery to the primate brain. Neuroimage 2008.
5. Fiandaca M.S., Forsayeth J.R., Dickinson P.J., Bankiewicz K.S. Image-guided convection-enhanced delivery platform in the treatment of neurological diseases. Neurotherapeutics 2008, 5(1):123-127.
6. Gill S.S., Patel N.K., Hotton G.R., O'Sullivan K., McCarter R., Bunnage M., et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003, 9(5):589-595.
7. Heiss J.D., Walbridge S., Morrison P., Hampton R.R., Sato S., Vortmeyer A., et al. Local distribution and toxicity of prolonged hippocampal infusion of muscimol. J Neurosurg 2005, 103(6):1035-1045.
8. Krauze M.T., Saito R., Noble C., Tamas M., Bringas J., Park J.W., et al. Reflux-free cannula for convection-enhanced high-speed delivery of therapeutic agents. J Neurosurg 2005, 103(5):923-929.
9. Kunwar S., Prados M.D., Chang S.M., Berger M.S., Lang F.F., Piepmeier J.M., et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J Clin Oncol 2007, 25(7):837-844.
10. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol. 2006, 59(3):459-466.
11. Marks W.J., Ostrem J.L., Verhagen L., Starr P.A., Larson P.S., Bakay R.A., et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 2008, 7(5):400-408.
12. Marks W.J., Stacy M. A Phase I/II Trial Assessing the Safety and Efficacy of Bilateral Intraputaminal and Intranigral Administration of CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN]) in Subjects with Idiopathic Parkinson's Disease). Minutes of the National Institutes of Health Recombinant DNA Advisory Committee 2009.
13. Morrison P.F., Chen M.Y., Chadwick R.S., Lonser R.R., Oldfield E.H. Focal delivery during direct infusion to brain: role of flow rate, catheter diameter, and tissue mechanics. Am J Physiol 1999, 277(4 Pt 2):R1218-1229.
14. Noble C.O., Krauze M.T., Drummond D.C., Yamashita Y., Saito R., Berger M.S., et al. Novel nanoliposomal CPT-11 infused by convection-enhanced delivery in intracranial tumors: pharmacology and efficacy. Cancer Res 2006, 66(5):2801-2806.
15. Saito N., Kimura T., Toma M., Sasaki K., Kita T., Imura M., et al. Transcatheter closure of patent ductus arteriosus with the Inoue single-branched stent graft. J Thorac Cardiovasc Surg 2005, 130(4):1203-1204.
16. Salvatore M.F., Ai Y., Fischer B., Zhang A.M., Grondin R.C., Zhang Z., et al. Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 2006, 202(2):497-505.
17. Sampson J.H., Archer G., Pedain C., Wembacher-Schroder E., Westphal M., Kunwar S., et al. Poor drug distribution as a possible explanation for the results of the PRECISE trial. J Neurosurg 2009.
18. Slevin J.T., Gerhardt G.A., Smith C.D., Gash D.M., Kryscio R., Young B., et al. Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 2005, 102(2):216-222.
19. Su X., Kells A.P., Huang E.J., Lee H.S., Hadaczek P., Beyer J., et al. Safety evaluation of AAV2-GDNF gene transfer into the dopaminergic nigrostriatal pathway in aged and parkinsonian rhesus monkeys. Hum Gene Ther 2009, 20(12):1627-1640.
20. Yin D., Valles F.E., Fiandaca M.S., Bringas J., Gimenez F., Berger M.S., et al. Optimal region of the putamen for image-guided convection-enhanced delivery of therapeutics in human and non-human primates. Neuroimage 2009.